Direxion Daily Financial Bull 3X Shares ETF
FAS
Spdr S&P Bank Etf
KBE
Ultra Financials Proshares
UYG
4
SPDR S&P Metals & Mining ETF
XME
5
SPDR S&P Retail ETF
XRT
US Stock MarketDetailed Quotes
Seres Therapeutics (MCRB)
- 16.200
- +0.300+1.89%
Close Dec 16 16:00 ET
- 16.200
- 0.0000.00%
Post 16:10 ET
146.55MMarket Cap50.63P/E (TTM)
16.625High15.900Low52.88KVolume16.000Open15.900Prev Close858.62KTurnover0.78%Turnover Ratio810.00P/E (Static)9.05MShares29.98052wk High3.35P/B109.41MFloat Cap6.53052wk Low--Dividend TTM6.75MShs Float1040.000Historical High--Div Yield TTM4.56%Range %6.530Historical Low16.237Avg Price1Lot Size
MCRB Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
MCRB Orderflow
Unit: --
MCRB Orderflow Trend
IntradayDayWeekMonth
No Data
Seres Therapeutics (MCRB) News
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
12 Health Care Stocks Moving In Thursday's Intraday Session
$MCRB Stock Is up 12% Today. Here's What We See in Our Data.
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $22
Canaccord Genuity Keeps Their Buy Rating on Seres Therapeutics (MCRB)
Earnings Call Summary | Seres Therapeutics(MCRB.US) Q3 2025 Earnings Conference
Seres Therapeutics (MCRB) Stock Forum
$Seres Therapeutics (MCRB.US)$ Seres Therapeutics Announces Further Constructive Feedback From FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
GlobeNewswire
3m
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies
Company continues to...
GlobeNewswire
3m
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies
Company continues to...
1
$Seres Therapeutics (MCRB.US)$ Item 5 - Approval of amendments to the Company’s Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”) to effect a reverse stock split.
Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes. 85,742,623. 29,461,090 187,192. 0
Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes. 85,742,623. 29,461,090 187,192. 0
$Seres Therapeutics (MCRB.US)$ going down to 55
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)